Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment.

Related Articles

Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment.

Oncotarget. 2018 Mar 06;9(18):14630-14641

Authors: Wei J, Zhu H, Liao X

Abstract
Purpose: To assess the relationship between the diagnostic accuracy of Choline positron emission tomography/computed tomography (PET/CT) and the trigger prostate-specific antigen (PSA) level in patients with a biochemical recurrence of prostate cancer.
Materials and Methods: A meta-analysis was conducted to synthesize data across multiple studies.
Results: The pooled sensitivity and specificity of choline PET/CT were 82% (95% Confidence Interval (CI):80-84%) and 92% (95%CI: 90-93%), respectively. The pooled sensitivity and specificity of 18F-choline PET/CT were 81% (95%CI: 78-84%) and 90% (95%CI: 85-93%), respectively. The pooled sensitivity and specificity of 11C-choline PET/CT were 83% (95% CI: 80-86%) and 92% (95% CI: 90-94%), respectively. The pooled detection rate of 18F-choline PET/CT and 11C-choline PET/CT were 58% (95% CI: 48-68%) and 58% (95%CI: 49-68%), respectively.
Conclusions: Trigger PSA is an important risk factor for positive findings of Choline PET/CT and the detection rate of Choline PET/CT for recurrent prostate cancer increased in parallel with raises in PSA-values. Choline PET/CT got higher detection rate while the trigger PSA > 2ng/ml.

PMID: 29581869 [PubMed]

https://ift.tt/2GhleYo